Comair to reduce operations further
Article Abstract:
Comair announced that it will make additional cuts in services in order to save capital and lower costs. The carrier will remarket 20 more jets, downsize more nonstriking workers, and layoff 200 additional pilots.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
Lufthansa to review operations in bid to control costs
Article Abstract:
Lufthansa announced it would review all of its businesses to control costs and ensure profitability. The group's new efficiency program would raise the group's earnings and add Euro1 million to the airline's cash flow over the next three years.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
UAL incurs $1.16 billion net loss amid effects of September attacks
Article Abstract:
UAL Corp. posted a net loss of $1.16 billion for the 2001 third-quarter, the carrier's worst loss in its entire history. UAL was hurt by the September 2001 World Trade Center attacks.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Lucent posts $8.8 billion loss due to costs of restructuring. Lucent profit soars by 41% to exceed analysts' estimates
- Abstracts: AMR posts $1.04 billion loss, and CEO's future is uncertain. Gillette picks ex-Nabisco CEO to be its chief executive
- Abstracts: KPN plans 5 billion euros share offering as part of restructuring to trim debt. KPN leads new issuance with 2 billion euros offering
- Abstracts: Lithuania garners E207 million to shut an aging nuclear plant. A tale of two city guides
- Abstracts: U.S. is setting a path for biotech generics: regulator plots a course for approving copycats of bioengineered medicines